What Rigevidon 21 + 7 FE Treats: Main Uses and Benefits

Rigevidon 21 + 7 FE is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It provides support that helps ease the overall symptom burden, contributing to enhanced comfort during symptomatic periods. The medication may also be used to help with period pain, heavy periods, and premenstrual syndrome (PMS).

This medication is commonly used across conditions presenting with acute episodes and is relevant when supportive symptom management is appropriate. It is applied in addressing symptom clusters that may become intense or disruptive, such as menstrual bleeding (menorrhagia), menstrual pain (dysmenorrhea), and hormonally driven acne. In these contexts, it helps manage associated symptoms and may support general well-being during symptomatic phases.

Contextual Note: Management of Symptom Load

Rigevidon is commonly used across conditions presenting with periods of heightened symptoms, which include disorders like Polycystic Ovary Syndrome (PCOS) and acute menstrual distress. It is used for managing symptoms related to systemic imbalance and those that interfere with daily functioning.

Who Can and Cannot Use Rigevidon 21 + 7 FE?

Eligibility for Rigevidon 21 + 7 FE is strictly defined by regulatory authorities to manage the risk of serious side effects, primarily blood clots (thrombosis). The medication is indicated for use by females of reproductive potential for contraception.

Populations and Conditions that Must Not Use Rigevidon

This medicine is contraindicated in several high-risk groups. Patients who have or have a history of the following conditions must not use this medicine:

• Vascular Disease: History of venous thromboembolism (VTE), such as DVT or pulmonary embolism, or arterial thromboembolism (ATE), such as a stroke or heart attack.
• Thrombotic Risk: Conditions like migraine with aura, uncontrolled hypertension, or diabetes mellitus with vascular complications.
• Cancer: Current or history of breast cancer or other known hormone-sensitive cancers.
• Liver Function: Severe liver disease or the presence of liver tumors (benign or malignant).

Use Limitations and Restrictions

• Age and Smoking: Females over age 35 who smoke are absolutely contraindicated.
• Pregnancy: The medicine is contraindicated during known or suspected pregnancy.
• Breastfeeding: Use is generally not recommended while breastfeeding.
• Surgery: Use must be discontinued before major surgery or during any period of prolonged immobilization due to the increased risk of VTE.

Interactions with other medicines and products

Interactions that reduce the effectiveness of this hormonal contraceptive are primarily due to medicines that increase the clearance of the active hormone components. These interactions can lead to breakthrough bleeding and potential contraceptive failure.

Medicinal Product Categories and Conditions

1. Enzyme-Inducing Medicines:

Certain medicinal products, such as those used to treat epilepsy (anticonvulsants like phenytoin, carbamazepine, and phenobarbital), HIV/AIDS, tuberculosis (rifampicin), and the herbal remedy St. John's wort (Hypericum perforatum), can induce liver enzymes. This induction increases the breakdown of the contraceptive hormones. For long-term treatment with enzyme-inducing substances, a highly reliable, non-hormonal method of contraception is recommended. If concurrent use is necessary, a barrier method must be used during the entire course of treatment and for 28 days after discontinuation.

2. Hepatitis C Antiviral Regimens:

Co-administration with specific combinations of antiviral agents, including those containing ombitasvir/paritaprevir/ritonavir and dasabuvir or glecaprevir/pibrentasvir, is restricted due to the potential for significant increases in liver enzyme levels (ALT elevation). The contraceptive must be stopped before initiating these treatments, and it can be restarted approximately 2 weeks after completion of the antiviral therapy.

3. Other Medicines Affected by Contraceptives:

This medicine can also affect the metabolism of other medicinal products. It may increase the concentration of drugs like ciclosporin in the blood plasma, or it may decrease the concentration of drugs such as lamotrigine.

HPO Axis Suppression: The Central Mechanism

Rigevidon 21 + 7 FE operates through a multi-component mechanism involving the synthetic steroid hormones ethinylestradiol and levonorgestrel. The primary action is the inhibition of ovulation via the suppression of the hypothalamic-pituitary-ovarian (HPO) axis. The active components exert a negative feedback on the pituitary gland, leading to reduced secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), a critical mechanism for the suppression of gonadotropin release, thereby preventing follicular maturation and subsequent ovum release.

Peripheral Biologic Effects

Simultaneously, levonorgestrel acts on the reproductive tract. This action includes an increase in the viscosity of cervical mucus, which creates a biophysical barrier to sperm migration. The combination of components also induces modifications to the endometrium, disrupting the required hormonal environment for implantation. The formulation’s structure, including the inactive tablets, is designed to maintain a constant level of active components throughout the cycle, contributing to sustained progestogenic effects.

How to Use Rigevidon 21 + 7 FE — Official Administration Guidelines

The usage of Rigevidon 21 + 7 FE is governed by a continuous, 28-day cyclic oral administration protocol. This approach mandates the sequential intake of both active and inactive tablets to maintain the dosing schedule.

---

Administration Scope

Instruction	Detail
Route of administration	Oral (by mouth).
Dosing schedule	One tablet daily for 28 consecutive days. The active tablets contain 150 micrograms Levonorgestrel and 30 micrograms Ethinylestradiol.
Timing in relation to meals	The tablet must be taken at approximately the same time point every day and may be taken with some liquid if necessary to assist swallowing.

---

Official Procedural Structure

The full course of administration is structured into a 28-day sequence, ensuring a continuous daily intake pattern:

• Sequence Adherence: Take the tablets in the order directed on the blister pack, starting with the 21 active tablets, followed by the 7 inactive tablets (containing Ferrous Fumarate).
• Cycle Continuity: A new 28-day blister pack must be started immediately after the previous pack is finished, without a tablet-free break.

Missed-Dose Rules (Time Constraints)

Official instructions specify the actions required following a delayed dose:

• Delay Less Than 12 Hours: If the forgotten active tablet is taken less than 12 hours late, protection is not reduced. The tablet must be taken immediately, and the remaining tablets should be taken at the usual time.
• Delay Exceeding 12 Hours: If the delay exceeds 12 hours, contraceptive protection may be reduced. Management depends on the specific week of the cycle. A fundamental rule is that tablet intake must never be delayed for longer than 7 days to maintain the required hormone suppression.

Research Evidence / Overview of Studies for Rigevidon 21 + 7 FE

Evidence for Use in Preventing Pregnancy (Contraception)

Rigevidon 21 + 7 FE was studied for its use in the field of contraception. Research examined how consistently outcomes related to contraceptive effectiveness were observed when the medication was used as directed in healthy women who were not pregnant. These studies typically monitored participants over defined time intervals to record outcomes related to contraceptive effectiveness.

The findings describe patterns observed in these studies and indicate that use of the medication was associated with a specific, low rate of pregnancy in the observed populations. Research highlights changes measured during the study period and provides insight into short-term outcomes related to systemic or functional imbalance.

---

Evidence for Use in Managing Heavy Menstrual Bleeding

Rigevidon 21 + 7 FE was also evaluated in research examining measured outcomes related to the menstrual cycle. Studies explored outcomes related to physical discomfort and systemic or functional imbalance in women who reported fluctuating or intense symptoms related to the menstrual cycle.

Studies report how patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning evolved in the observed populations. Findings indicate patterns where, in some studies, the use of the medication was associated with changes in outcomes reflecting daily functioning or activity level as reported by participants monitoring physiological strain or stress related to the menstrual flow.

---

Long-term Studies and Follow-up

Research explored the long-term experience of women using Rigevidon 21 + 7 FE. Studies monitored how outcomes related to physical discomfort and systemic or functional imbalance changed over extended time intervals. These studies often follow participants after the initial trial to understand the durability of observed changes.

The findings help contextualize how patients reported their experience over years of use. While some research describes the patterns observed for several years, it is important to understand that the results apply only to the populations studied, and long-term effects are not fully established.

---

Evidence in Special Populations

Studies in Different Age Groups

Rigevidon 21 + 7 FE was evaluated in research contexts involving adolescents and younger women. Research has examined patterns related to short-term changes in these groups.

Evidence in Women with Specific Health Conditions

Research has also examined Rigevidon 21 + 7 FE in women with certain comorbid health conditions, but this evidence is often limited. These studies monitor physiological strain or stress in populations presenting with cycles of stability and flare-ups related to other health issues.

---

What is Still Uncertain About Rigevidon 21 + 7 FE

This section synthesizes the main gaps identified in the research. While many studies were conducted, areas of uncertainty remain.

Specifically, comparative evidence is lacking between Rigevidon 21 + 7 FE and other similar products. Follow-up durations were limited in many trials, meaning the long-term effects are not fully established.

Key Studies & References

1. Heavy menstrual bleeding: assessment and management (NICE Guideline NG88)
2. Risk of venous thromboembolism with combined oral contraceptives: a systematic review and meta-analysis

Common questions about Rigevidon 21 + 7 FE (FAQ)

---

Q: What generation of combined oral contraceptive is Rigevidon 21+7 FE classified as?

Rigevidon is generally categorized as a second-generation combined oral contraceptive (COC). This classification is based on its specific hormonal composition, which includes the progestogen Levonorgestrel.

---

Q: Is it still necessary to use barrier methods of contraception when starting Rigevidon 21+7 FE?

Official administration guidance specifies that starting the active tablets on day 2 through 5 of the menstrual cycle requires using a barrier method of contraception for the first 7 days. If the medication is started on the first day of the menstrual cycle, full contraceptive protection is considered to be established immediately, provided it is taken correctly.

---

Q: Can Rigevidon 21+7 FE be taken continuously to avoid having a withdrawal bleed?

Official product information describes that it is possible to delay a withdrawal bleed by skipping the 7 inactive tablets and immediately starting a new pack of active tablets. This approach is generally used to shift or postpone a period. However, official information notes that breakthrough bleeding may still occur while continuing to take the active tablets.

---

Q: Is protection against pregnancy maintained during the 7 days of taking the inactive (FE) tablets?

Provided the 21 hormone-active tablets were taken correctly in the previous cycle, contraceptive protection is expected to be maintained during the 7-day inactive tablet interval. This is because the active hormones have established the necessary suppression of ovulation during the active-pill phase.

---

Q: What are the signs or symptoms of a blood clot that are listed in the Rigevidon 21+7 FE patient information leaflet?

Patient safety information highlights the rare but serious risk of blood clots (thromboembolism). Warning signs listed often include sudden severe chest pain, weakness or numbness in the face or limbs, or pain and swelling in one leg. These signs are listed as potential indicators of rare, serious conditions such as pulmonary embolism, stroke, and deep vein thrombosis.

---

Q: Are there any known changes to cholesterol or triglyceride levels associated with this medication?

Official adverse reaction data notes that enhanced levels of blood fat, a condition known as severe dyslipoproteinaemia, are a possible rare side effect. This refers to the potential for changes in blood fat levels, which is classified as a rare adverse reaction.

---

Q: Is it mentioned in official sources that Rigevidon 21+7 FE can interfere with the results of any medical tests?

Yes, according to official product information, hormonal contraceptives can affect the results of certain laboratory tests. This includes tests related to liver, thyroid, and kidney function, as well as blood-clotting factors (coagulation parameters).

---

Q: Is Rigevidon 21+7 FE known to affect the ability to wear contact lenses comfortably?

Regulatory documents list irritation when wearing contact lenses as a possible uncommon adverse reaction. If new or increasing irritation occurs when wearing contact lenses, regulatory information suggests this may be a possible uncommon adverse reaction.

---

Q: What is the general information available regarding the return of the menstrual cycle after stopping Rigevidon 21+7 FE?

Fertility generally returns shortly after the medication is discontinued, as the effects are fully reversible. However, official clinical context suggests that it may take up to three cycles for the body's natural cycle and regular menstruation pattern to fully resume.

---

Q: Does Rigevidon 21+7 FE provide any protection against sexually transmitted diseases (STDs)?

No, according to official special warnings, hormonal contraceptives like this one do not protect against HIV infection (AIDS) or any other sexually transmissible diseases. Only barrier methods, like condoms, provide protection against STDs.

---

Q: Can I use Rigevidon 21+7 FE if I have a history of Crohn's disease or ulcerative colitis?

Official safety documentation does not list Crohn’s disease or ulcerative colitis as absolute contraindications. However, severe malabsorption syndromes, such as active Inflammatory Bowel Disease (IBD), are noted as potentially reducing the contraceptive effectiveness of the tablet.

---

Q: What are the typical instructions for starting Rigevidon 21+7 FE for the first time?

Regulatory guidance indicates that starting the tablets on the first day of the natural menstrual cycle means contraceptive protection is immediately established. If the start date is delayed to day 2 through 5 of the cycle, a supplemental barrier method is required for the first seven days of active pill intake.

---

Q: Can digestive issues like vomiting or severe diarrhea reduce the effectiveness of Rigevidon 21+7 FE?

Official guidance states that if vomiting or severe diarrhoea occurs within 3 to 4 hours of taking an active tablet, the absorption of the hormones may be incomplete. In this situation, the event should be handled as if a dose was missed, and the specific instructions for missed doses should be followed.

---

Q: How quickly does the contraceptive effect of Rigevidon 21+7 FE start after the first pill is taken?

Contraceptive protection is generally considered to be established immediately if the first active tablet is taken on the first day of the menstrual period. If the first tablet is taken later than day one of the cycle, additional contraceptive measures, such as a barrier method, are necessary for the first seven days of active tablet use.

---

Q: Does Rigevidon 21+7 FE affect a woman's fertility after she stops taking the medication?

Official regulatory information indicates that the medication does not cause permanent infertility. The contraceptive effects are fully reversible, and fertility typically returns shortly after discontinuation, though it may take a few months for the natural menstrual cycle to re-establish its regular pattern.

---

Q: What are the components of the 'withdrawal bleed' experienced during the placebo week?

The bleeding experienced during the inactive tablet week is technically a withdrawal bleed, not a true menstrual period. It occurs when the supply of hormones is withdrawn during the inactive tablet period, causing the uterine lining (endometrium) to shed. This bleed typically begins on the second or third day of taking the inactive tablets.

The storage and disposal of Rigevidon 21 + 7 FE must align strictly with the requirements documented in official regulatory labeling.

Storage Requirements

Labeled Storage Temperature Requirements:	Store below 25 C (77 F)
Packaging-Related Storage Rules:	Keep tablets in the original container/blister pack
Child-Protection Storage Requirements:	Keep the medicine out of the sight and reach of children

The official labeling mandates that the product be stored below the specified maximum temperature to maintain its stability until the expiry date. No special handling or environmental protection (e.g., protection from light or moisture) is explicitly listed beyond this temperature constraint.

Official Disposal Instructions

Disposal Instructions (as documented):	Do not throw away via wastewater or household waste
Required Disposal Procedure:	Return unused or expired medicines to a pharmacist

Disposal must follow the established pharmaceutical waste protocol: unused or expired tablets must be returned to a pharmacist to ensure the procedure helps to protect the environment.